CDAK Average Annual Return Since 2020
Growth of $10,000.00
Without Dividends Reinvested Into CDAK

Also see:
CDAK stock yearly return 2021
CDAK stock yearly return 2022
CDAK YTD return
Compare CDAK average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 10/15/2020
End date: 04/04/2023
Start price/share: $12.09
End price/share: $0.06
Dividends collected/share: $0.00
Total return: -99.53%
CDAK Average Annual Return: -88.58%
Starting investment: $10,000.00
Ending investment: $47.19
Years: 2.47

CDAK average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. One of Co.'s clinical stage programs, exoSTING, is an exosome therapeutic candidate delivering its proprietary STING agonist while expressing high levels of Prostaglandin F2 receptor negative regulator (PTGFRN) on the exosome surface to facilitate specific uptake in tumor-resident antigen-presenting cells. Co.'s other clinical stage program, exoIL-12, displays IL-12 in an active form on the surface of the engineered exosome. Co.'s third clinical stage program, exoASO-STAT6, overexpresses PTGFRN to selectively target uptake in M2-polarized tumor-associated-macrophages. The CDAK average annual return since 2020 is shown above.

The Average Annual Return on the CDAK average annual return since 2020 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CDAK average annual return since 2020 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CDAK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CDAK Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Codiak BioSciences (CDAK) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CDMO Average Annual Return
CDNA Average Annual Return
CDRE Average Annual Return
CDTX Average Annual Return
CDXC Average Annual Return
CELC Average Annual Return
CELZ Average Annual Return
CEMI Average Annual Return
CERE Average Annual Return
CERS Average Annual Return
More Healthcare companies »


CDAK Average Annual Return Since 2020 | | Copyright © 2021 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.